Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 4,825 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 4,825 shares of the business’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $16.26, for a total value of $78,454.50. Following the transaction, the director now owns 3,702,595 shares of the company’s stock, valued at $60,204,194.70. The trade was a 0.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Tyra Biosciences Trading Down 2.4 %

Shares of NASDAQ TYRA opened at $15.50 on Tuesday. The company has a fifty day moving average price of $15.38 and a 200 day moving average price of $19.12. Tyra Biosciences, Inc. has a 1-year low of $12.48 and a 1-year high of $29.60. The firm has a market cap of $784.35 million, a PE ratio of -9.63 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Upgrades and Downgrades

TYRA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, January 13th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $31.00 in a research report on Friday, October 18th. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has a consensus rating of “Buy” and a consensus price target of $30.50.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC grew its position in Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences in the third quarter valued at about $311,000. Oppenheimer & Co. Inc. raised its holdings in Tyra Biosciences by 9.0% during the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock worth $1,806,000 after acquiring an additional 6,318 shares in the last quarter. Quest Partners LLC acquired a new position in Tyra Biosciences during the third quarter valued at approximately $491,000. Finally, Jennison Associates LLC grew its stake in Tyra Biosciences by 5.9% in the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock valued at $3,719,000 after purchasing an additional 8,837 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.